INTRODUCTION: Parkinson's disease (PD) is poorly quantified by patients outside the clinic, and paper diaries have problems with subjective descriptions and bias. Wearable sensor platforms; however, can accurately quantify symptoms such as tremor, dyskinesia, and bradykinesia. Commercially available smartwatches are equipped with accelerometers and gyroscopes that can measure motion for objective evaluation. We sought to evaluate the clinical utility of a prescription smartwatch-based monitoring system for PD utilizing periodic task-based motor assessment. METHODS: Sixteen patients with PD used a smartphone- and smartwatch-based monitoring system to objectively assess motor symptoms for 1 week prior to instituting a doctor recommended change in therapy and for 4 weeks after the change. After 5 weeks the participants returned to the clinic to discuss their results with their doctor, who made therapy recommendations based on the reports and his clinical judgment. Symptom scores were synchronized with the medication diary and the temporal effects of therapy on weekly and hourly timescales were calculated. RESULTS: Thirteen participants successfully completed the study and averaged 4.9 assessments per day for 3 days per week during the study. The doctor instructed 8 participants to continue their new regimens and 5 to revert to their previous regimens. The smartwatch-based assessments successfully captured intraday fluctuations and short- and long-term responses to therapies, including detecting significant improvements (p < 0.05) in at least one symptom in 7 participants. CONCLUSIONS: The smartwatch-based app successfully captured temporal trends in symptom scores following application of new therapy on hourly, daily, and weekly timescales. These results suggest that validated smartwatch-based PD monitoring can provide clinically relevant information and may reduce the need for traditional office visits for therapy adjustment.
INTRODUCTION: Parkinson's disease (PD) is poorly quantified by patients outside the clinic, and paper diaries have problems with subjective descriptions and bias. Wearable sensor platforms; however, can accurately quantify symptoms such as tremor, dyskinesia, and bradykinesia. Commercially available smartwatches are equipped with accelerometers and gyroscopes that can measure motion for objective evaluation. We sought to evaluate the clinical utility of a prescription smartwatch-based monitoring system for PD utilizing periodic task-based motor assessment. METHODS: Sixteen patients with PD used a smartphone- and smartwatch-based monitoring system to objectively assess motor symptoms for 1 week prior to instituting a doctor recommended change in therapy and for 4 weeks after the change. After 5 weeks the participants returned to the clinic to discuss their results with their doctor, who made therapy recommendations based on the reports and his clinical judgment. Symptom scores were synchronized with the medication diary and the temporal effects of therapy on weekly and hourly timescales were calculated. RESULTS: Thirteen participants successfully completed the study and averaged 4.9 assessments per day for 3 days per week during the study. The doctor instructed 8 participants to continue their new regimens and 5 to revert to their previous regimens. The smartwatch-based assessments successfully captured intraday fluctuations and short- and long-term responses to therapies, including detecting significant improvements (p < 0.05) in at least one symptom in 7 participants. CONCLUSIONS: The smartwatch-based app successfully captured temporal trends in symptom scores following application of new therapy on hourly, daily, and weekly timescales. These results suggest that validated smartwatch-based PD monitoring can provide clinically relevant information and may reduce the need for traditional office visits for therapy adjustment.
Authors: Marios Politis; Kit Wu; Sophie Molloy; Peter G Bain; K Ray Chaudhuri; Paola Piccini Journal: Mov Disord Date: 2010-08-15 Impact factor: 10.338
Authors: Stuart H Isaacson; Babak Boroojerdi; Olga Waln; Martha McGraw; David L Kreitzman; Kevin Klos; Fredy J Revilla; Dustin Heldman; Maureen Phillips; Dolors Terricabras; Michael Markowitz; Franz Woltering; Stan Carson; Daniel Truong Journal: Parkinsonism Relat Disord Date: 2019-01-28 Impact factor: 4.891
Authors: R A Hauser; J Friedlander; T A Zesiewicz; C H Adler; L C Seeberger; C F O'Brien; E S Molho; S A Factor Journal: Clin Neuropharmacol Date: 2000 Mar-Apr Impact factor: 1.592
Authors: Alberto J Espay; Jeffrey M Hausdorff; Álvaro Sánchez-Ferro; Jochen Klucken; Aristide Merola; Paolo Bonato; Serene S Paul; Fay B Horak; Joaquin A Vizcarra; Tiago A Mestre; Ralf Reilmann; Alice Nieuwboer; E Ray Dorsey; Lynn Rochester; Bastiaan R Bloem; Walter Maetzler Journal: Mov Disord Date: 2019-03-22 Impact factor: 10.338
Authors: Christopher G Goetz; Barbara C Tilley; Stephanie R Shaftman; Glenn T Stebbins; Stanley Fahn; Pablo Martinez-Martin; Werner Poewe; Cristina Sampaio; Matthew B Stern; Richard Dodel; Bruno Dubois; Robert Holloway; Joseph Jankovic; Jaime Kulisevsky; Anthony E Lang; Andrew Lees; Sue Leurgans; Peter A LeWitt; David Nyenhuis; C Warren Olanow; Olivier Rascol; Anette Schrag; Jeanne A Teresi; Jacobus J van Hilten; Nancy LaPelle Journal: Mov Disord Date: 2008-11-15 Impact factor: 10.338
Authors: Dustin A Heldman; Denzil A Harris; Timothy Felong; Kelly L Andrzejewski; E Ray Dorsey; Joseph P Giuffrida; Barry Goldberg; Michelle A Burack Journal: Digit Biomark Date: 2017-05-12